Please ensure Javascript is enabled for purposes of website accessibility

Novavax Publishes Coronavirus Vaccine Phase 1 Data in The New England Journal of Medicine

By Brian Orelli, PhD – Sep 3, 2020 at 7:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The details look as good as the initial report.

Novavax (NVAX 0.60%) announced last month that its coronavirus vaccine, NVX-CoV2373, induced antibodies in all participants treated in its phase 1 clinical trial. But investors can now take a closer look at the exact levels of antibody production in the peer-reviewed data that was published in The New England Journal of Medicine on Wednesday.

Patients given the vaccine combined with Matrix-M adjuvant, which increases the immune response to the coronavirus protein in the vaccine, developed levels of antibodies able to bind to the novel coronavirus that were at a similar level to patients who were exposed to the novel coronavirus but were largely asymptomatic. After a booster dose, the antibody levels increased to at least six times what was seen in symptomatic outpatient patients who had COVID-19 and reached similar levels to patients hospitalized with COVID-19.

Novavax also looked specifically at neutralizing antibodies, which not only bind to the novel coronavirus but do so in a way that blocks the virus from infecting the patient's cells. After the second vaccination, participants receiving the adjuvanted vaccine had levels of neutralizing antibodies that were four times greater than symptomatic outpatients with COVID-19, and about half the level seen in hospitalized patients with COVID-19.

Healthcare working showing a syringe to a child

Image source: Getty Images.

In addition to inducing the production of antibodies, the adjuvanted vaccine also induced a response from T cells, which are responsible for seeking out infected cells and destroying them before the infection can spread.

Novavax has started the phase 2 portion of the study in the U.S. and Australia. It's also testing the vaccine in a phase 2b study in South Africa.

The biotech trails multiple coronavirus vaccine-makers in phase 3 development, but may still have an opportunity to capture some patients if the leaders aren't able to show their vaccines protect against COVID-19, or aren't able to manufacture enough vaccine to meet demand.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$16.64 (0.60%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.